LifeMD, Inc. Files 2023 Annual Report on Form 10-K

Ticker: LFMDP · Form: 10-K · Filed: Mar 11, 2024 · CIK: 948320

Sentiment: neutral

Topics: 10-K, LifeMD, Annual Report, Healthcare, Telehealth

TL;DR

<b>LifeMD, Inc. has filed its annual report detailing its 2023 financial performance and business operations.</b>

AI Summary

LifeMD, Inc. (LFMDP) filed a Annual Report (10-K) with the SEC on March 11, 2024. LifeMD, Inc. filed its 2023 Form 10-K on March 11, 2024. The filing covers the fiscal year ending December 31, 2023. The company's principal executive offices are located at 236 Fifth Avenue, Suite 400, New York, NY 10001. LifeMD, Inc. was formerly known as Conversion Labs, Inc. and Immudyne, Inc. The SIC code for LifeMD, Inc. is 8011, Services-Offices & Clinics of Doctors of Medicine.

Why It Matters

For investors and stakeholders tracking LifeMD, Inc., this filing contains several important signals. This 10-K filing provides a comprehensive overview of LifeMD's financial health, operational strategies, and risk factors for the fiscal year 2023, crucial for investors assessing the company's current standing and future prospects. The detailed financial statements and disclosures within the report are essential for understanding the company's revenue streams, profitability, and any potential challenges it faces in the telehealth and healthcare services market.

Risk Assessment

Risk Level: medium — LifeMD, Inc. shows moderate risk based on this filing. The company operates in the highly regulated healthcare industry, facing potential risks from changes in healthcare laws, reimbursement policies, and compliance requirements, which could materially impact its financial performance.

Analyst Insight

Investors should review the detailed risk factors and financial statements in the 10-K to assess LifeMD's ability to navigate regulatory challenges and achieve sustainable growth.

Key Numbers

Key Players & Entities

FAQ

When did LifeMD, Inc. file this 10-K?

LifeMD, Inc. filed this Annual Report (10-K) with the SEC on March 11, 2024.

What is a 10-K filing?

A 10-K is a comprehensive annual financial report required by the SEC, covering audited financials, business operations, risk factors, and management discussion. This particular 10-K was filed by LifeMD, Inc. (LFMDP).

Where can I read the original 10-K filing from LifeMD, Inc.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by LifeMD, Inc..

What are the key takeaways from LifeMD, Inc.'s 10-K?

LifeMD, Inc. filed this 10-K on March 11, 2024. Key takeaways: LifeMD, Inc. filed its 2023 Form 10-K on March 11, 2024.. The filing covers the fiscal year ending December 31, 2023.. The company's principal executive offices are located at 236 Fifth Avenue, Suite 400, New York, NY 10001..

Is LifeMD, Inc. a risky investment based on this filing?

Based on this 10-K, LifeMD, Inc. presents a moderate-risk profile. The company operates in the highly regulated healthcare industry, facing potential risks from changes in healthcare laws, reimbursement policies, and compliance requirements, which could materially impact its financial performance.

What should investors do after reading LifeMD, Inc.'s 10-K?

Investors should review the detailed risk factors and financial statements in the 10-K to assess LifeMD's ability to navigate regulatory challenges and achieve sustainable growth. The overall sentiment from this filing is neutral.

Risk Factors

Key Dates

Filing Stats: 4,268 words · 17 min read · ~14 pages · Grade level 15.4 · Accepted 2024-03-11 16:30:56

Key Financial Figures

Filing Documents

BUSINESS

ITEM 1. BUSINESS 4

RISK FACTORS

ITEM 1A. RISK FACTORS 12

UNRESOLVED STAFF COMMENTS

ITEM 1B. UNRESOLVED STAFF COMMENTS 27

CYBERSECURITY

ITEM 1C. CYBERSECURITY 27

PROPERTIES

ITEM 2. PROPERTIES 27

LEGAL PROCEEDINGS

ITEM 3. LEGAL PROCEEDINGS 27

MINE SAFETY DISCLOSURES

ITEM 4. MINE SAFETY DISCLOSURES 27 PART II

MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS, AND ISSUER PURCHASES OF EQUITY SECURITIES

ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS, AND ISSUER PURCHASES OF EQUITY SECURITIES 28

RESERVED

ITEM 6. RESERVED 28

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 28

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 36

FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA 36

CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE 36

CONTROLS AND PROCEDURES

ITEM 9A. CONTROLS AND PROCEDURES 36

OTHER INFORMATION

ITEM 9B. OTHER INFORMATION 38

DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS

ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS 38 PART III

DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE 39

EXECUTIVE COMPENSATION

ITEM 11. EXECUTIVE COMPENSATION 39

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS 39

CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE 39

PRINCIPAL ACCOUNTANT FEES AND SERVICES

ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES 39 PART IV

EXHIBITS, FINANCIAL STATEMENT SCHEDULES

ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES 40

FORM 10-K SUMMARY

ITEM 16. FORM 10-K SUMMARY 43

SIGNATURES

SIGNATURES 44 2 FORWARD-LOOKING CAUTIONARY The following discussion should be read in conjunction with the financial statements and related notes contained elsewhere in this Annual Report on Form 10-K. Certain statements made in this discussion are "forward-looking statements" within the meaning of 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). These statements are based upon beliefs of, and information currently available to, the Company's management as well as estimates and assumptions made by the Company's management. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. When used herein, the words "anticipate," "believe," "estimate," "expect," "forecast," "future," "intend," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue" or the negative of these terms and similar expressions as they relate to the Company or the Company's management identify forward-looking statements. Such statements reflect the current view of the Company with respect to future events and are subject to risks, uncertainties, assumptions, and other factors, including the risks relating to the Company's business, industry, and the Company's operations and results of operations. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ materially from those anticipated, believed, estimated, expected, intended, or planned. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, levels of activity, performance, or achievements

business

business interruptions resulting from geo-political actions, including war, and terrorism or disease outbreaks. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, or performance. Readers are urged to carefully review and consider the various disclosures made by us in this report and in our other reports filed with the Securities and Exchange Commission ("SEC"), including the risk factors identified in Item 1A of this report. We undertake no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes in the future operating results over time except as required by law. We believe that our assumptions are based upon reasonable data derived from and known about our business and operations. No assurances are made that actual results of operations or the results of our future activities will not differ materially from our assumptions. Our consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States ("GAAP"). These accounting principles require us to make certain estimates, judgments, and assumptions. We believe that the estimates, judgments, and assumptions upon which we rely are reasonable based upon information available to us at the time that these estimates, judgments and assumptions are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities as of the date of the consolidated financial statements as well as the reported amounts of revenues and expenses during the periods presented. Our consolidated financial statements would be affected to the extent there are material differences between these estimates and actual results. The following discussion should be read in conjunction with our financial statements and notes thereto appearing elsewhere in this report. A

Business

Business Overview We are a direct-to-patient telehealth company providing a high-quality, cost-effective, and convenient way to access comprehensive, virtual and in-home healthcare. We believe the traditional model of visiting a doctor's office, traveling to a retail pharmacy, and returning for follow up care or prescription refills is complex, inefficient, and costly, and discourages many individuals from seeking much needed medical care. LifeMD is improving the delivery of healthcare experience through telehealth with our proprietary technology platform, affiliated and dedicated provider network, broad and expanding treatment capabilities, and unique ability to nurture patient relationships. The LifeMD telehealth platform integrates best-in-class capabilities including a 50-state medical group, a nationwide pharmacy network, nationwide laboratory and diagnostic testing capabilities, a fully integrated electronic medical records ("EMR") system and an internal patient care and service call center. These capabilities are integrated by an industry-leading, proprietary telehealth technology that supports a broad range of primary care, chronic disease and lifestyle healthcare needs. Currently, LifeMD treats over 215,000 active patient subscribers across a range of their medical needs including primary care, men's sexual health, weight management, sleep, hair loss and hormonal therapy by providing telehealth clinical services and prescription and over-the-counter ("OTC") treatments, as medically appropriate. Our virtual primary care services are primarily offered on a subscription basis. Since inception, we have helped approximately 854,000 customers and patients by providing them greater access to high-quality, convenient, and affordable care. Our mission is to empower people to live healthier lives by increasing access to high-quality and affordable virtual and in-home healthcare. We believe our success has been, and will continue to be, attributable to an amazin

View Full Filing

View this 10-K filing on SEC EDGAR

View on Read The Filing